



COLLEGE OF PHYSICIANS  
SINGAPORE

# COLLEGE OF PHYSICIANS, SINGAPORE

## ACADEMY OF MEDICINE, SINGAPORE



ACADEMY OF MEDICINE  
SINGAPORE

2021 – 2022

### COUNCIL MEMBERS

**Dr David Lye**  
President

**Dr Terence Kee**  
Vice-President

**Dr Lee Lai Heng**  
Honorary Secretary

**Dr Faith Chia**  
Honorary Treasurer

**Dr Bok Chek Wai**  
Council Member

**Dr Lau Tang Ching**  
Council Member

**Dr Ng Heng Joo**  
Council Member

### CHAPTER AND SECTION CHAIRS

**Dr Michael Lim**  
Chair, Chapter of Cardiologists

**Dr Tee Shang-lan**  
Chair, Chapter of Dermatologists

**Dr Kurumbian Chandran**  
Chair, Chapter of Endocrinologists

**Dr Chua Tju Siang**  
Chair, Chapter of Gastroenterologists

**Dr Nihar Pandit**  
Chair, Chapter of General Physicians

**Dr Tan Thai Lian**  
Chair, Chapter of Geriatricians

**Dr Lee Lai Heng**  
Chair, Chapter of Haematologists

**Dr Asok Kurup**  
Chair, Chapter of Infectious Disease  
Physicians

**Dr Joline Lim**  
Chair, Chapter of Medical Oncologists

**Dr Raymond Seet**  
Chair, Chapter of Neurologists

**Dr Peh Tan Ying**  
Chair, Chapter of Palliative Medicine  
Physicians

**Dr Sherry Young**  
Chair, Chapter of Rehabilitation  
Physicians

**Dr Manish Kaushik**  
Chair, Chapter of Renal Physicians

**Dr Jansen Koh**  
Chair, Chapter of Respiratory  
Physicians

**Dr Manjari Lahiri**  
Chair, Chapter of Rheumatologists

**Dr Bernard Thong**  
Chair, Section of Clinical  
Immunologists and Allergists

## CALL FOR SPONSORSHIP/EDUCATIONAL GRANT

### 1. OVERVIEW & OBJECTIVE

The Chapter of Renal Physicians under the College of Physicians, Singapore, together with the Academy of Medicine, Singapore, plans to organize a free webinar on **Use of SGLT2-Inhibitors in non-DM CKD and Stage 4 CKD: An Appraisal of Current Evidence.**

The Chapter is delighted to invite sponsorship/educational grant for this event. It is hoped that the exposure and program will be of mutual benefit and we look forward to co-operating with your company to make this endeavor an untold success.

### 2. FRAMEWORK FOR PROPOSED WEBINAR

Organizers	1. Chapters of Renal Physicians under the College of Physicians, Singapore 2. Academy of Medicine, Singapore (AMS)
Co-organizer(s)	NA
Date:	21 September 2021
Duration:	~1 to 1.5-hr CME/CPD accredited webinar
Mode:	Online electronic means (ZOOM)
Target Audience:	~300pax comprising medical practitioners in Singapore and beyond
Programme:	Please refer to Annex 1

### 3. CHAPTER and ACADEMY'S OBLIGATIONS

Programme:	To develop, produce and host the webinar
Secretariat Support & Admin:	Provide secretariat support to organise, publicise and manage the programmes; attend to CME accreditation and submission of CME attendance; and production of webinar.

### 4. OPPORTUNITIES FOR SPONSOR

Sponsorship:	Sponsor will endow an educational grant of \$5,000 to cover cost of organizing and running the webinar, speakers' honorarium, subscription of webinar platform, technical and manpower support, and processing of CME accreditation and credits.
Registration:	FREE

Benefits/Mileage:	<ol style="list-style-type: none"> <li>1. Sponsors will be recognized and named as the sponsor in program marketing materials.</li> <li>2. Acknowledgement of sponsor during webinar</li> <li>3. Enable sponsor to invite their contact/clients to join in the webinar</li> </ol>
Closing Date:	10 September 2021
Note:	Sponsor will have no influence/input on the CME/CPD programme.
<b>4. EXPRESS OF INTEREST</b>	
Contact:	<p>If you would like to sponsor for the webinar or require more details, please contact:</p> <p><i>Secretariat</i></p> <p><b>Ms Samantha Sukiyama CHAN</b>  Email: <a href="mailto:cps@ams.edu.sg">cps@ams.edu.sg</a> DID: 6593 7868</p>

# **Webinar on Use of SGLT2-Inhibitors in non-DM CKD and Stage 4 CKD: An Appraisal of Current Evidence**

*by Professor David Collins Wheeler*

21 September 2021, Tuesday

6:00 – 7:30pm

## **Programme:**

6.00pm Welcome and Introduction by Dr Manish Kaushik

6.10pm Lecture by *Professor David Collins Wheeler*

7:00pm Panel Discussion and Q&A

7.30pm Closing and End of Webinar

## **Synopsis:**

Sodium glucose co-transporter inhibitors were developed as drugs to improve glycaemic control in patients with type 2 diabetes. In cardiovascular safety studies mandated by regulatory agencies, these drugs reduced the risk of cardiovascular events (particularly heart failure) and improved markers of chronic kidney disease. In recent studies specifically targeting patients with heart failure and chronic kidney disease, outcome benefits have been shown to be largely independent of improvements in glycaemic control and to extent to patients who do not have type 2 diabetes. The precise mechanisms underlying the cardiorenal protective effects of SGLT2 inhibitors are not fully understood, but the clinical benefits have become clear. Physicians should be aware of these recent developments and consider prescribing these drugs to appropriate patients with CKD and heart failure whether or not they have diabetes as a comorbidity.

## **About Professor David Collins Wheeler**

Professor of Kidney Medicine

University College London, UK